{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:22:16Z","timestamp":1785900136669,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ahj.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T18:28:19Z","timestamp":1611426499000},"page":"82-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities"],"prefix":"10.1016","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3619-966X","authenticated-orcid":false,"given":"Nancy M.","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel J.","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Larry","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Herbert","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredonia B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.01.017_bib0001","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT Trial: A secondary analysis of a randomized clinical trial","volume":"5","author":"Fiuzat","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0002","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.471","article-title":"The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database","volume":"18","author":"Maggioni","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0004","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.ahj.2021.01.017_bib0005","doi-asserted-by":"crossref","first-page":"e0172745","DOI":"10.1371\/journal.pone.0172745","article-title":"Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients","volume":"12","author":"Farr\u00e9","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ahj.2021.01.017_bib0006","doi-asserted-by":"crossref","first-page":"e004646","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646","article-title":"Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the Get With The Guidelines-Heart Failure registry","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0007","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00392-019-01430-0","article-title":"Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry","volume":"108","author":"Ergatoudes","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0008","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/ejhf.1202","article-title":"Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study","volume":"20","author":"Iorio","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijcard.2018.05.001","article-title":"Heart failure and sleep related breathing disorders: data from PROMISES (Progetto Multicentrico Italiano Sonno e Scompenso Cardiaco) study","volume":"271","author":"Lombardi","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jchf.2019.09.004","article-title":"Impact of age on comorbidities and outcomes in heart failure with reduced ejection fraction","volume":"7","author":"Regan","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0011","doi-asserted-by":"crossref","first-page":"e016502","DOI":"10.1161\/JAHA.120.016502","article-title":"Association of diagnostic coding-based frailty and outcomes in patients with heart failure: a report from the veterans affairs health system","volume":"9","author":"Kohsaka","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2021.01.017_bib0012","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3399\/bjgp19X702725","article-title":"Comorbidity in patients with cardiovascular disease in primary care: a cohort study with routine healthcare data","volume":"69","author":"Buddeke","year":"2019","journal-title":"Br J Gen Pract."},{"key":"10.1016\/j.ahj.2021.01.017_bib0013","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.jacc.2017.04.049","article-title":"How to use beta-blockers in heart failure with reduced ejection fraction and atrial fibrillation","volume":"69","author":"Filippatos","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0014","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cardfail.2018.10.005","article-title":"Low utilization of beta-blockers among medicare beneficiaries hospitalized for heart failure with reduced ejection fraction","volume":"25","author":"Loop","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ehf2.12055","article-title":"Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges","volume":"2","author":"Lainscak","year":"2015","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0016","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cardfail.2008.11.015","article-title":"Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction","volume":"15","author":"Yumino","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0017","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.amjcard.2019.05.054","article-title":"Frequency of utilization of beta blockers in patients with heart failure and depression and their effect on mortality","volume":"124","author":"Kim","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0018","doi-asserted-by":"crossref","first-page":"e005899","DOI":"10.1161\/JAHA.116.005899","article-title":"SchlaHF Investigators. Phenotyping of sleep-disordered breathing in patients with chronic heart failure with reduced ejection fraction-the SchlaHF registry","volume":"6","author":"Arzt","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.ahj.2021.01.017_bib0019","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.01.017_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchf.2020.08.017","article-title":"Heart failure hospitalization and guideline-directed prescribing patterns among heart failure with reduced ejection fraction patients","volume":"9","author":"Srivastava","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0021","doi-asserted-by":"crossref","first-page":"e3721","DOI":"10.1097\/MD.0000000000003721","article-title":"Angiotensin-receptor blocker, angiotensin-converting enzyme inhibitor, and risks of atrial fibrillation","volume":"95","author":"Hsieh","year":"2016","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.ahj.2021.01.017_bib0022","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1074248415619490","article-title":"Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Chaugai","year":"2016","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ahj.2021.01.017_bib0023","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/europace\/euy311","article-title":"Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study","volume":"21","author":"De With","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2021.01.017_bib0024","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/eurheartj\/ehx739","article-title":"Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial","volume":"39","author":"Rienstra","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2021.01.017_bib0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/ehjcvp\/pvv019","article-title":"Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease","volume":"1","author":"Campo","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ahj.2021.01.017_bib0026","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ejhf.964","volume":"20","author":"Canepa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0027","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/clc.22738","article-title":"Obstructive sleep apnea is associated with increased readmission in heart failure patients","volume":"40","author":"Sommerfeld","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0028","doi-asserted-by":"crossref","first-page":"e4059","DOI":"10.1097\/MD.0000000000004059","article-title":"Effect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: a meta-analysis and systematic review of randomized controlled trials","volume":"95","author":"Chaugai","year":"2016","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.ahj.2021.01.017_bib0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12916-018-1104-9","article-title":"Medications that reduce emergency hospital admissions: an overview of systematic reviews and prioritisation of treatments","volume":"16","author":"Bobrovitz","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ahj.2021.01.017_bib0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ahj.2017.04.010","article-title":"Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry","volume":"189","author":"DeVore","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2021.01.017_bib0031","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCOUTCOMES.115.001958","article-title":"Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire","volume":"8","author":"Spertus","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ahj.2021.01.017_bib0032","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12872-018-0808-2","article-title":"Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: Insights from the NCDR PINNACLE\u00ae registry","volume":"18","author":"Allen","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ahj.2021.01.017_bib0033","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/fampra\/cmx135","article-title":"RECODE-HF study group. Importance of comorbidities in the treatment of primary care patients with heart failure \u2013 Baseline results of the observational RECODE-HF study","volume":"35","author":"Eisele","year":"2018","journal-title":"Fam Pract"},{"key":"10.1016\/j.ahj.2021.01.017_bib0034","doi-asserted-by":"crossref","unstructured":"Burnett H, Earley A, Voors AA, et\u00a0al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Hear Fail. 2017;10:e003539. doi:10.1161\/CIRCHEARTFAILURE.116.003529.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529"},{"key":"10.1016\/j.ahj.2021.01.017_bib0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"CHECK-HF investigators. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0036","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0037","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00392-015-0939-8","article-title":"General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study","volume":"105","author":"Hirt","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0038","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0039","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10741-016-9575-2","article-title":"The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice","volume":"21","author":"Chin","year":"2016","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ahj.2021.01.017_bib0040","first-page":"448","article-title":"Chronic kidney disease and atrial fibrillation: a contemporary overview","volume":"5","author":"Kulkarni","year":"2012","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.ahj.2021.01.017_bib0041","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.01.017_bib0042","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ehf2.12185","article-title":"Impaired renal function affects clinical outcomes and management of patients with heart failure","volume":"4","author":"Jenkins","year":"2017","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ahj.2021.01.017_bib0043","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321000284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321000284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:06:53Z","timestamp":1757570813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":43,"alternative-id":["S0002870321000284"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.01.017","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}